Deciphering the Shared Genetics of Bipolar Disorder and BMI

Clinicians frequently encounter metabolic dysregulation among psychiatric patients, making the relationship between bipolar disorder and BMI a critical clinical concern. Epidemiological evidence consistently documents high rates of obesity and metabolic syndrome in individuals diagnosed with bipolar disorder. However, whether this co-occurrence stems from shared biological underpinnings, psychotropic medication side effects, or lifestyle patterns has sparked prolonged debate. A comprehensive study by Ma and colleagues directly investigated this intersection by evaluating large-scale genome-wide association study datasets. The researchers applied linkage disequilibrium score regression alongside Heritability Estimation from Summary Statistics to quantify both global and local genetic overlap. Consequently, their computational findings confirm that shared genomic factors link these two complex conditions. Furthermore, localized genomic regions showed prominent genetic correlations that shed light on mutual biological vulnerabilities. Psychiatric patients carrying higher genetic risk burdens often struggle with metabolic complications even before initiating pharmacotherapy. Therefore, establishing a true genetic overlap helps clinicians differentiate intrinsic biological liabilities from treatment-emergent adverse effects. By validating these shared pathways, researchers provide clinicians with a clearer framework for personalized patient care. This foundational genomic evidence also reinforces the necessity of early metabolic surveillance in psychiatric settings.

Cross-Trait Meta-Analysis Discovers Novel Shared Loci

To identify specific genomic loci driving this correlation, the authors conducted a rigorous cross-trait meta-analysis. This analytical approach revealed 46 significant single nucleotide polymorphisms that show joint association with both bipolar disorder and elevated body mass index. Notably, the investigation uncovered three novel shared risk variants that earlier single-phenotype studies failed to detect. In addition, stratified linkage disequilibrium score regression characterized how these overlapping signals distribute across diverse functional genomic categories. The researchers mapped these pleiotropic single nucleotide polymorphisms to identify common regulatory elements and downstream biochemical pathways. Moreover, these identified loci illuminate shared molecular perturbations that influence neuroendocrine signaling and energy balance simultaneously. In clinical practice, psychiatrists frequently observe rapid weight changes during acute mood episodes. These common genetic variants explain why certain individuals develop severe weight fluctuations regardless of caloric intake. Additionally, identifying shared risk variants opens promising avenues for developing targeted therapies that address psychiatric and metabolic burdens collectively. As genomic repositories continue to expand, such pleiotropic variants will play pivotal roles in risk stratification. Ultimately, mapping these shared loci helps bridge the longstanding gap between clinical psychiatry and systemic endocrinology.

Colocalization Analysis Implicates ITIH1 and TM6SF2 Genes

Statistical correlation alone cannot prove that two distinct traits share an identical causal variant. Therefore, the investigative team deployed Bayesian colocalization analysis to evaluate whether bipolar disorder and body mass index share genuine causal mutations. This rigorous validation technique confirmed two novel single nucleotide polymorphisms that demonstrate shared causal architecture at specific loci. Specifically, the colocalization analysis implicated the inter-alpha-trypsin inhibitor heavy chain 1 gene, known as ITIH1, alongside TM6SF2. The ITIH1 gene participates in neuroinflammation, extracellular matrix stability, and brain connectivity pathways that influence psychiatric disease vulnerability. In contrast, TM6SF2 plays well-established roles in hepatic lipid metabolism, cellular fat export, and metabolic cardiovascular risk. Consequently, finding shared variation at these loci connects central nervous system functioning with systemic lipid regulation. This molecular overlap suggests that dysregulated inflammatory cascades and lipid transport mechanisms may jointly exacerbate mood instability and adiposity. Furthermore, these genomic findings highlight potential biological targets for pharmacological interventions designed to minimize metabolic liability. Understanding these shared gene functions allows clinicians to anticipate metabolic vulnerability in psychiatric patients with greater biological precision. Thus, functional genomics offers indispensable clues regarding the systemic pathology underlying neuropsychiatric disorders.

Mendelian Randomization Demonstrates Unidirectional Causality

Observational studies regularly fail to establish whether mood disorders trigger weight gain or whether obesity predisposes individuals to bipolar pathology. To address this classic clinical dilemma, the researchers performed bi-directional Mendelian randomization using genetic instruments as natural randomizers. This epidemiological technique effectively minimizes typical confounding variables and circumvents reverse causality. Importantly, the Mendelian randomization analysis demonstrated a clear causal effect of bipolar disorder liability on increasing body mass index. Conversely, the reverse analysis showed that genetically predicted higher body mass index does not cause bipolar disorder. Therefore, genetic liability toward bipolar illness directly drives changes in body weight through physiological and behavioural pathways. Mood destabilization, circadian disruption, and chronic neuroendocrine alterations likely initiate downstream metabolic derangements. Moreover, these findings suggest that metabolic disturbances represent core biological sequelae of bipolar pathophysiology rather than incidental secondary phenomena. Physicians must recognize that patients with bipolar disorder face inherent biological risks for progressive weight gain. Consequently, proactive metabolic interventions must begin immediately at the point of psychiatric diagnosis. Addressing these downstream metabolic consequences early preserves overall cardiovascular and neurocognitive outcomes.

Tissue Enrichment Across Brain Regions and Integrated Patient Care

The researchers next investigated tissue-level single nucleotide polymorphism heritability enrichment using transcriptomic profiles and multi-marker genomic annotation. Their analysis demonstrated that genetic correlation signals between bipolar disorder and body mass index show pronounced enrichment across five distinct brain regions. These regions encompass central regulatory centers that govern emotional stability, reward processing, appetite homeostasis, and impulse control. Consequently, dysfunction across these shared neural circuits provides a compelling neurobiological substrate for comorbid affective illness and metabolic dysregulation. In clinical practice, these insights demand a paradigm shift from siloed mental healthcare to comprehensive cardiometabolic management. Clinicians should establish baseline anthropometric and metabolic parameters, including fasting glucose, lipid profiles, and waist circumference, prior to treatment initiation. Furthermore, prescribers should carefully weigh the metabolic side effect profiles of mood stabilizers and second-generation antipsychotics. Selecting weight-neutral psychotropics when feasible can protect vulnerable patients from accelerated metabolic deterioration. In addition, integrating structured nutritional counseling, exercise regimens, and regular endocrinological monitoring directly improves long-term treatment adherence. Ultimately, viewing bipolar disorder through this integrated genetic and metabolic lens empowers clinicians to deliver holistic, life-extending therapeutic strategies.

Does elevated body mass index increase the genetic risk of bipolar disorder?

No, current Mendelian randomization analyses indicate that higher body mass index does not cause bipolar disorder. Instead, the genetic liability flows unidirectionally from bipolar disorder toward higher adiposity. Underlying neuroendocrine alterations, affective instability, and circadian rhythm disruption driven by bipolar pathology appear to trigger subsequent metabolic disturbances and weight gain.

Which specific genes link bipolar disorder and body mass index?

Colocalization analyses highlight two primary genes: ITIH1 and TM6SF2. ITIH1 influences neurodevelopment, neuroinflammation, and cellular structural integrity within the central nervous system. Conversely, TM6SF2 governs hepatic lipid metabolism and circulating triglyceride secretion. Together, these pleiotropic genes illustrate how neuroimmune dysregulation and abnormal systemic lipid processing converge in affected individuals.

How should clinicians adjust treatment based on this shared genetic liability?

Clinicians should implement baseline cardiometabolic screening before initiating psychotropic therapy, monitoring lipid panels, blood glucose, and body mass index regularly. Prescribers should prioritize weight-neutral psychiatric medications whenever clinically feasible. In addition, integrating lifestyle modifications, dietary education, and routine endocrinology collaboration helps prevent long-term metabolic complications in this genetically vulnerable patient population.

Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Ma H et al. Deciphering the shared genetic architecture between bipolar disorder and body mass index. J Affect Disord. 2025 Jun 15. doi: 10.1016/j.jad.2025.03.002. PMID: 40056998.

Winther R et al. Genetic liability to bipolar disorder and body mass index: A bidirectional two-sample Mendelian randomization study. Bipolar Disord. 2023;25(5):393-401.

Bahrami S et al. Shared genetic architecture between obesity and psychiatric disorders reveals comorbid etiology and therapeutic targets. Oxford Open Immunol. 2026;7(1):iqae012.